Activity in these models may open the way for new approaches for treating various sporadic cancers with E-cadherin deficiency [7,8,9,10], and may reduce the likelihood of early HDGC lesions developing therapy resistance through additional oncogenic events. The gene discussed is CDH1; the disease is Familial gastric cancer.